ClinicalTrials.gg
CompletedNCT05048719Updated Oct 17, 2023Results posted

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

A Phase 2 interventional study of LY3502970 and Dulaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 44 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
10th of 15
383 · median 546
Started
2021
with 1 other
Phase 2
Only one
of the 15
Registered
2nd of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 2, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
  • Have a stable body weight for the 3 months prior to randomization
  • Have a (BMI) ≥23 kilogram/square meter (kg/m²)
  • Males must agree to use highly effective methods of
  • Women not of (WNOCBP) may participate in this trial
  • Note: Hormone replacement therapy in women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
  • Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
  • Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
  • Have acute or chronic pancreatitis
  • Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
  • Have gastric emptying abnormality or chronically take medications impacting GI motility
  • Have poorly controlled hypertension
  • Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
  • Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
  • Have , or or
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    3 milligrams (mg) LY3502970

    Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).

    Drug: LY3502970

  • Experimental
    12 mg LY3502970

    Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.

    Drug: LY3502970

  • Experimental
    24 mg LY3502970

    Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.

    Drug: LY3502970

  • Experimental
    36 mg LY3502970 - 1

    Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

    Drug: LY3502970

  • Experimental
    36 mg LY3502970 - 2

    Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

    Drug: LY3502970

  • Experimental
    45 mg LY3502970 - 1

    Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

    Drug: LY3502970

  • Experimental
    45 mg LY3502970 - 2

    Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

    Drug: LY3502970

  • Active comparator
    1.5 mg Dulaglutide

    Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).

    Drug: Dulaglutide

  • Placebo comparator
    Placebo

    Participants received matching placebo.

    Drug: Placebo

Interventions

  • Administered orally

  • Administered subcutaneously

  • DrugPlacebo

    Administered orally

  • DrugPlacebo

    Administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c in LY3502970 as Compared to Placebo

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 26

  2. Percentage of Participants With HbA1c ≤ 6.5%

    Percentage of Participants with HbA1c ≤ 6.5%. Odds ratio was calculated using logistic regression model.

    Time frame: Week 26

  3. Percentage of Participants With HbA1c <7.0%

    Percentage of Participants with HbA1c \<7.0%. Odds ratio was calculated using logistic regression model.

    Time frame: Week 26

  4. Change From Baseline in Fasting Serum Glucose

    Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, 8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 26

  5. Change From Baseline in Body Weight

    LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 26

  6. Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970

    PK: Steady State AUC of LY3502970

    Time frame: Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).

07

Results

Posted Oct 17, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg Dulaglutide
Started555156472734313250
Received at least one dose of study drug555156472734313250
Completed514750422530292949
Not completed446524231
Withdrew: Withdrawal by subject213102110
Withdrew: Death100000000
Withdrew: Adverse event012010000
Withdrew: Lost to follow-up001311110
Withdrew: Physician decision000000011
Withdrew: Patient decision due to changes in personal life100000000
Withdrew: Participant was unresponsive and too far out of window to resume treatment010000000
Withdrew: Sponsor decision due to inadvertent enrollment010000000
Withdrew: Participant decided to discontinue treatment and only return for single final visit000100000
Withdrew: Site terminated participant due to sponsor directions000001000

Outcome measures

PrimaryChange From Baseline in HbA1c in LY3502970 as Compared to Placebo

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c in LY3502970 as Compared to Placebo
Percentage of HbA1c3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Change From Baseline in HbA1c in LY3502970 as Compared to Placebo-1.19 ± 0.137-1.91 ± 0.133-1.79 ± 0.149-2.03 ± 0.127-2.10 ± 0.124-0.43 ± 0.128
Statistical analysis
  • 3 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.77 · 95% CI -1.13 to -0.40
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.49 · 95% CI -1.85 to -1.12
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.36 · 95% CI -1.75 to -0.98
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.60 · 95% CI -1.96 to -1.25
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.67 · 95% CI -2.02 to -1.32
SecondaryChange From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide
Percentage of HbA1c3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY350297045 mg LY35029701.5 mg Dulaglutide
Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide-1.19 ± 0.137-1.91 ± 0.133-1.79 ± 0.149-2.03 ± 0.127-2.10 ± 0.124-1.10 ± 0.131
Statistical analysis
  • 3 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = 0.626 · Ls mean difference: -0.09 · 95% CI -0.47 to 0.28
  • 12 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.81 · 95% CI -1.18 to -0.44
  • 24 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.69 · 95% CI -1.08 to -0.30
  • 36 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.93 · 95% CI -1.29 to -0.57
  • 45 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.00 · 95% CI -1.36 to -0.64
SecondaryPercentage of Participants With HbA1c ≤ 6.5%

Percentage of Participants with HbA1c ≤ 6.5%. Odds ratio was calculated using logistic regression model.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c ≤ 6.5%
Percentage of participants3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo1.5 mg Dulaglutide
Percentage of Participants With HbA1c ≤ 6.5%45.3070.7380.1279.3983.5214.5641.04
Statistical analysis
  • 3 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.77 · 95% CI 2.21 to 20.75
  • 12 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 34.09 · 95% CI 9.92 to 117.16
  • 24 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 48.33 · 95% CI 11.90 to 196.24
  • 36 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 45.72 · 95% CI 13.61 to 153.64
  • 45 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 77.23 · 95% CI 20.26 to 294.48
  • 3 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = 0.678 · Odds ratio (or): 1.22 · 95% CI 0.48 to 3.13
  • 12 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.15 · 95% CI 2.19 to 17.24
  • 24 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.71 · 95% CI 2.55 to 29.79
  • 36 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.24 · 95% CI 3.05 to 22.30
  • 45 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 13.93 · 95% CI 4.51 to 43.01
SecondaryPercentage of Participants With HbA1c <7.0%

Percentage of Participants with HbA1c \<7.0%. Odds ratio was calculated using logistic regression model.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c <7.0%
Percentage of participants3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo1.5 mg Dulaglutide
Percentage of Participants With HbA1c <7.0%65.1778.9291.2492.7595.7624.2764.06
Statistical analysis
  • 3 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.19 · 95% CI 2.93 to 22.90
  • 12 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 25.02 · 95% CI 7.57 to 82.69
  • 24 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 62.31 · 95% CI 12.26 to 316.63
  • 36 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 67.57 · 95% CI 17.56 to 259.97
  • 45 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 129.55 · 95% CI 26.72 to 628.09
  • 3 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = 0.802 · Odds ratio (or): 1.13 · 95% CI 0.43 to 2.96
  • 12 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = 0.026 · Odds ratio (or): 3.46 · 95% CI 1.16 to 10.31
  • 24 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = 0.006 · Odds ratio (or): 8.61 · 95% CI 1.83 to 40.51
  • 36 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 9.34 · 95% CI 2.67 to 32.71
  • 45 mg LY3502970 vs 1.5 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 17.90 · 95% CI 4.02 to 79.70
SecondaryChange From Baseline in Fasting Serum Glucose

Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, 8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose
milligrams per deciliter (mg/dL)3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo1.5 mg Dulaglutide
Change From Baseline in Fasting Serum Glucose-32.6 ± 4.14-53.7 ± 3.92-52.2 ± 4.49-53.9 ± 3.79-55.9 ± 3.69-11.1 ± 3.90-33.2 ± 3.91
Statistical analysis
  • 3 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -21.5 · 95% CI -32.7 to -10.3
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -42.5 · 95% CI -53.4 to -31.7
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -41.0 · 95% CI -52.7 to -29.3
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -42.7 · 95% CI -53.5 to -32.0
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -44.7 · 95% CI -55.3 to -34.2
  • 3 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: 0.6 · 95% CI -10.6 to 11.8
  • 12 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -20.5 · 95% CI -31.4 to -9.5
  • 24 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = 0.002 · Ls mean difference: -19.0 · 95% CI -30.7 to -7.2
  • 36 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -20.7 · 95% CI -31.4 to -9.9
  • 45 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -22.7 · 95% CI -33.2 to -12.1
SecondaryChange From Baseline in Body Weight

LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo1.5 mg Dulaglutide
Change From Baseline in Body Weight-3.7 ± 0.79-6.5 ± 0.76-9.7 ± 0.85-9.5 ± 0.73-10.1 ± 0.71-2.2 ± 0.74-3.9 ± 0.76
Statistical analysis
  • 3 mg LY3502970 vs Placebo · Mixed Models Analysis · p = 0.153 · Ls mean difference: -1.6 · 95% CI -3.7 to 0.6
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -4.3 · 95% CI -6.4 to -2.2
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -7.6 · 95% CI -9.8 to -5.3
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -7.4 · 95% CI -9.4 to -5.3
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -7.9 · 95% CI -9.9 to -5.9
  • 3 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = 0.914 · Ls mean difference: 0.1 · 95% CI -2.0 to 2.3
  • 12 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = 0.015 · Ls mean difference: -2.6 · 95% CI -4.7 to -0.5
  • 24 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -5.9 · 95% CI -8.1 to -3.6
  • 36 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -5.7 · 95% CI -7.8 to -3.6
  • 45 mg LY3502970 vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.2 · 95% CI -8.3 to -4.2
SecondaryPharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970

PK: Steady State AUC of LY3502970

Time frame:
Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
Reported as:
Geometric mean · nanogram *hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970
nanogram *hour per milliliter (ng*h/mL)3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 2
Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970364 ± 38.71020 ± 63.51500 ± 84.51830 ± 94.62430 ± 39.82230 ± 80.42550 ± 55.3

Adverse events

Collected over Baseline Through Safety Follow-Up (Up To Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/55 (1.8%)3/55 (5.5%)25/55 (45.5%)
3 mg LY35029700/51 (0%)3/51 (5.9%)34/51 (66.7%)
12 mg LY35029700/56 (0%)1/56 (1.8%)40/56 (71.4%)
24 mg LY35029700/47 (0%)5/47 (10.6%)32/47 (68.1%)
36 mg LY3502970 - 10/27 (0%)1/27 (3.7%)21/27 (77.8%)
36 mg LY3502970 - 20/34 (0%)1/34 (2.9%)18/34 (52.9%)
45 mg LY3502970 - 10/31 (0%)0/31 (0%)21/31 (67.7%)
45 mg LY3502970 - 20/32 (0%)1/32 (3.1%)23/32 (71.9%)
1.5 mg Dulaglutide0/50 (0%)1/50 (2%)23/50 (46%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPlacebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg Dulaglutide
Ischaemic strokeNervous system disorders1/550/510/560/471/270/340/310/320/50
Diabetic ketoacidosisMetabolism and nutrition disorders0/550/510/560/470/270/340/311/320/50
HypoglycaemiaMetabolism and nutrition disorders0/550/510/560/470/271/340/310/320/50
Urethral haemorrhageRenal and urinary disorders0/550/510/560/470/271/340/310/320/50
Gastrointestinal haemorrhageGastrointestinal disorders0/550/510/561/470/270/340/310/320/50
Pancreatitis acuteGastrointestinal disorders0/550/510/561/470/270/340/310/320/50
PylorospasmGastrointestinal disorders0/550/510/561/470/270/340/310/320/50
Varices oesophagealGastrointestinal disorders0/550/510/561/470/270/340/310/320/50
AppendicitisInfections and infestations0/550/510/561/470/270/340/310/320/50
DehydrationMetabolism and nutrition disorders0/550/510/561/470/270/340/310/320/50
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPlacebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg Dulaglutide
NauseaGastrointestinal disorders3/5512/5121/5616/4710/279/349/318/329/50
VomitingGastrointestinal disorders1/553/5112/5613/479/277/3411/317/324/50
DiarrhoeaGastrointestinal disorders4/5511/519/567/477/272/349/319/326/50
ConstipationGastrointestinal disorders1/557/517/566/476/271/341/314/320/50
EructationGastrointestinal disorders0/554/512/563/475/273/342/311/321/50
HeadacheNervous system disorders0/557/512/562/470/271/342/314/320/50
DyspepsiaGastrointestinal disorders2/556/514/563/473/272/342/312/321/50
FlatulenceGastrointestinal disorders1/550/510/564/473/271/341/311/321/50
Weight decreasedInvestigations0/550/512/562/473/272/341/310/320/50
Decreased appetiteMetabolism and nutrition disorders0/553/513/562/472/271/342/313/322/50

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg DulaglutideTotal
Mean58.30 ± 9.5259.00 ± 9.4357.40 ± 9.2360.50 ± 9.1159.20 ± 9.0760.10 ± 9.3758.10 ± 10.6358.90 ± 8.1858.80 ± 10.1958.90 ± 9.40
Sex: Female, Male
Sex: Female, Male(Participants)Placebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg DulaglutideTotal
Female27252017916101320157
Male282636301818211930226
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg DulaglutideTotal
Hispanic or Latino1471556776774
Not Hispanic or Latino414441422127242643309
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg DulaglutideTotal
American Indian or Alaska Native1011000104
Asian0111100015
Native Hawaiian or Other Pacific Islander0000000000
Black or African American42520023422
White504749432533292844348
More than one race0100110014
Unknown or Not Reported0000000000
Region of Enrollment
Region of Enrollment(Participants)Placebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg DulaglutideTotal
Hungary108983664963
Poland1113111069761285
Slovakia1081095556765
United States242226201314131622170
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)Placebo3 mg LY350297012 mg LY350297024 mg LY350297036 mg LY3502970 - 136 mg LY3502970 - 245 mg LY3502970 - 145 mg LY3502970 - 21.5 mg DulaglutideTotal
Mean8.1 ± 0.98.0 ± 0.88.2 ± 0.98.2 ± 0.98.0 ± 0.78.1 ± 0.88.3 ± 1.08.0 ± 0.88.0 ± 0.78.1 ± 0.8
08

Study locations

44 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • Touro University California
    Vallejo, California 94592, United States
  • New West Physicians Clinical Research
    Golden, Colorado 80401, United States
  • Optumcare Colorado Springs - Monument
    Monument, Colorado 80132, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Family Medical Associates
    Levittown, Pennsylvania 19056, United States
  • Tristar Clinical Investigations
    Philadelphia, Pennsylvania 19114, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • Bandera Family Health Care
    San Antonio, Texas 78249, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Capital Clinical Research Center
    Olympia, Washington 98502, United States
  • Eastside Research Associates
    Redmond, Washington 98052, United States
  • Bugát Pál Kórház
    Gyongyos, Heves 3200, Hungary
  • Kanizsai Dorottya Korhaz
    Nagykanizsa, Zala 8800, Hungary
  • Zala Megyei Szent Rafael Kórház
    Zalaegerszeg, Zala 8900, Hungary
  • Szent Margit Rendelőintézet Nonprofit Kft
    Budapest, 1032, Hungary
  • Clinexpert Kft.
    Budapest, 1033, Hungary
  • ClinDiab Kft.
    Budapest, 1089, Hungary
  • TRANTOR'99 Bt. Anyagcsere Centrum
    Budapest, 1213, Hungary
  • Strazsahegy Medicina Bt.
    Budapest, H1171, Hungary
  • Wojewódzki Zespól Specjalistycznej Opieki Zdrowotnej
    Wrocław, Dolnośląskie 50-403, Poland
  • Gabinety TERPA
    Lublin, Lubelskie 20-333, Poland
  • NZOZ Medica
    Lublin, Lubelskie 20-538, Poland
  • Centralny Szpital Kliniczny MSWiA w Warszawie
    Warszawa, Mazowieckie 02-507, Poland
  • Centrum Zdrowia Tuchów
    Wierzchosławice, Małopolskie 33-122, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o.
    Gdansk, Pomorskie 80-546, Poland
  • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
    Lodz, Łódzkie, Poland
  • NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki
    Ruda Slaska, Śląskie 41-709, Poland
  • Dorado Medical Complex
    Dorado, 00646, Puerto Rico
  • Clinical Research Management Group Inc. - Hospital San Cristobal
    Ponce, 00780, Puerto Rico
  • BRCR Global Puerto Rico-Unda
    San Juan, 00907, Puerto Rico
  • Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA
    Bratislava, Bratislavský Kraj 831 06, Slovakia
  • Diabetol
    Prešov, Prešovský Kraj 080 01, Slovakia
  • MEDI-DIA s.r.o.
    Sabinov, Prešovský Kraj 083 01, Slovakia
  • DIA-MED CENTRUM s.r.o.
    Puchov, Trenčiansky Kraj 020 01, Slovakia
  • Funkystuff
    Nove Zamky, 940 01, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Sep 2022, 12 months.

Results were first posted in Oct 2023, 1 year after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 12 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Sep 17, 2021
StartActual
Sep 15, 2021
Primary completionActual
Sep 30, 2022
CompletionActual
Sep 30, 2022
Results first posted
Oct 17, 2023
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05048719
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Sep 15, 2021
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Results posted
Oct 17, 2023
Last update
Oct 17, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion